Matthew David Hellmann
Memorial Sloan Kettering Cancer Center · 807 works · 99,275 citations · h-index 118
Top works
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- OncoKB: A Precision Oncology Knowledge Base
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer